{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:16:03Z","timestamp":1791486963715,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The phase 2 PACE (Ponatinib Ph+ ALL and CML Evaluation) trial of ponatinib showed robust long-term benefit in relapsed Philadelphia chromosome-positive (Ph+) leukemia; arterial occlusive events (AOEs) occurred in\u2009\u2265\u200925% of patients based on investigator reporting. However, AOE rates vary depending on the definitions and reporting approach used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To better understand clinically relevant AOEs with ponatinib, an independent cardiovascular adjudication committee reviewed 5-year AOE data from the PACE trial according to a charter-defined process and standardized event definitions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 449 patients with chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) received ponatinib (median age 59 y; 47% female; 93%\u2009\u2265\u20092 prior tyrosine kinase inhibitors (TKIs); median follow-up, 37.3\u00a0months). The adjudicated AOE rate (17%) was lower than the non-adjudicated rate (i.e., rate before adjudication; 25%). The only adjudicated AOE in\u2009&gt;\u20092% of patients was peripheral arterial occlusive disease (4%). Exposure-adjusted incidence of newly occurring adjudicated AOEs decreased over time. Patients with multiple baseline cardiovascular risk factors had higher adjudicated AOE rates than those without risk factors.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This independent adjudication study identified lower AOE rates than previously reported, suggesting earlier overestimation that may inaccurately reflect AOE risk with ponatinib. This trial was registered under ClinicalTrials.gov identifier NCT01207440 on September 23, 2010 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01207440\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01207440<\/jats:ext-link>).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-021-01221-z","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T11:02:44Z","timestamp":1641466964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1798","authenticated-orcid":false,"given":"James L.","family":"Januzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Garasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Kasner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Seltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellin","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouryadeep","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Naranjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"1221_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401\u201312.","journal-title":"Cancer Cell"},{"key":"1221_CR2","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783\u201396.","journal-title":"N Engl J Med"},{"key":"1221_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393\u2013404.","journal-title":"Blood"},{"key":"1221_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00277-018-3337-2","volume":"97","author":"M Breccia","year":"2018","unstructured":"Breccia M, Abruzzese E, Castagnetti F, et al. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. Ann Hematol. 2018;97:1577\u201380.","journal-title":"Ann Hematol"},{"key":"1221_CR5","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/j.clml.2018.05.002","volume":"18","author":"A Shacham-Abulafia","year":"2018","unstructured":"Shacham-Abulafia A, Raanani P, Lavie D, et al. Real-life experience with ponatinib in chronic myeloid leukemia: a multicenter observational study. Clin Lymphoma Myeloma Leuk. 2018;18:e295\u2013301.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1221_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hon.2606","volume":"37","author":"G Caocci","year":"2019","unstructured":"Caocci G, Mulas O, Abruzzese E, et al. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematol Oncol. 2019;37:296\u2013302.","journal-title":"Hematol Oncol"},{"key":"1221_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.exphem.2018.08.006","volume":"67","author":"M Heiblig","year":"2018","unstructured":"Heiblig M, Rea D, Chretien ML, et al. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. Exp Hematol. 2018;67:41\u20138.","journal-title":"Exp Hematol"},{"issue":"Suppl 1","key":"1221_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2020-137577","volume":"136","author":"AO Ashaye","year":"2020","unstructured":"Ashaye AO, Thomas C, Dalal M, et al. Treatment of newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia using tyrosine kinase inhibitors in combination with chemotherapy: a patient-centered benefit-risk assessment [abstract]. Blood. 2020;136(Suppl 1):20\u20131.","journal-title":"Blood"},{"issue":"suppl 1","key":"1221_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2020-133922","volume":"136","author":"HM Kantarjian","year":"2020","unstructured":"Kantarjian HM, Deininger MW, Abruzzese E, et al. Efficacy and safety of ponatinib (PON) in patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed one or more second-generation (2G) tyrosine kinase inhibitors (TKIs): analyses based on PACE and Optic [abstract]. Blood. 2020;136(suppl 1):43\u20134.","journal-title":"Blood"},{"key":"1221_CR10","unstructured":"Hicks KA, Hung HMJ, Mahaffey KW, et al. Standardized definitions for cardiovascular and stroke endpoint events in clinical trials. 2014. Available at https:\/\/www.cdisc.org\/system\/files\/all\/standard\/Draft%20Definitions%20for%20CDISC%20August%2020%2C%202014.pdf. Accessed 14 Nov 2019."},{"key":"1221_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"KA Hicks","year":"2015","unstructured":"Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (writing committee to develop cardiovascular endpoints data standards). J Am Coll Cardiol. 2015;66:403\u201369.","journal-title":"J Am Coll Cardiol"},{"key":"1221_CR12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","volume":"137","author":"KA Hicks","year":"2018","unstructured":"Hicks KA, Mahaffey KW, Mehran R, et al. 2017 cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137:961\u201372.","journal-title":"Circulation"},{"key":"1221_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","volume":"2","author":"J Douxfils","year":"2016","unstructured":"Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogne JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2:625\u201332.","journal-title":"JAMA Oncol"},{"key":"1221_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","volume":"3","author":"P Jain","year":"2019","unstructured":"Jain P, Kantarjian H, Boddu PC, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019;3:851\u201361.","journal-title":"Blood Adv"},{"key":"1221_CR15","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib versus imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"1221_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440\u201353.","journal-title":"Leukemia"},{"key":"1221_CR17","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1182\/blood.V122.21.2726.2726","volume":"122","author":"D Rea","year":"2013","unstructured":"Rea D, Mirault T, Raffoux E, et al. Identification of patients (pts) with chronic myeloid leukemia (CML) at high risk of artery occlusive events (AOE) during treatment with the 2nd generation tyrosine kinase inhibitor (TKI) nilotinib, using risk stratification for cardiovascular diseases (CVD) [abstract]. Blood. 2013;122:2726.","journal-title":"Blood"},{"key":"1221_CR18","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2015","unstructured":"Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood. 2015;125:901\u20136.","journal-title":"Blood"},{"key":"1221_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","volume":"48","author":"DJ Dorer","year":"2016","unstructured":"Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84\u201391.","journal-title":"Leuk Res"},{"key":"1221_CR20","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood.2020006911","volume":"136","author":"J Cortes","year":"2020","unstructured":"Cortes J. How to manage CML patients with comorbidities. Blood. 2020;136:2507\u201312.","journal-title":"Blood"},{"key":"1221_CR21","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"1221_CR22","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648\u201371.","journal-title":"Leukemia"},{"key":"1221_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3324\/haematol.2012.064337","volume":"98","author":"A Russo Rossi","year":"2013","unstructured":"Russo Rossi A, Breccia M, Abruzzese E, et al. Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica. 2013;98:399\u2013403.","journal-title":"Haematologica"},{"key":"1221_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/10245332.2017.1385193","volume":"23","author":"S Ongoren","year":"2018","unstructured":"Ongoren S, Eskazan AE, Suzan V, et al. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology. 2018;23:212\u201320.","journal-title":"Hematology"},{"key":"1221_CR25","unstructured":"Guidance for Industry Diabetes Mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Available at https:\/\/www.fda.gov\/media\/71297\/download. Accessed 1 Apr 2021."},{"key":"1221_CR26","first-page":"13903","volume":"85","author":"US Food and Drug Administration","year":"2020","unstructured":"US Food and Drug Administration. Type 2 diabetes mellitus: evaluating the safety of new drugs for improving glycemic control; draft guidance for industry; availability. Fed Regist. 2020;85:13903\u20135.","journal-title":"Fed Regist"},{"key":"1221_CR27","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210\u20138.","journal-title":"J Clin Oncol"},{"key":"1221_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","volume":"32","author":"BC Medeiros","year":"2018","unstructured":"Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing. Blood Rev. 2018;32:289\u201399.","journal-title":"Blood Rev"},{"key":"1221_CR29","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes J, Apperley JF, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042\u201350.","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1186\/s13045-022-01239-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000}}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01221-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-021-01221-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01221-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T07:03:35Z","timestamp":1648019015000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01221-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1186\/s13045-021-01221-z","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13045-022-01239-x","asserted-by":"object"}]},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"21 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13045-022-01239-x","URL":"https:\/\/doi.org\/10.1186\/s13045-022-01239-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PACE was approved by local ethics committees and was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation guidelines for good clinical practice. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have critically reviewed the manuscript and consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.L.J.: Consulting\/advisory role (Takeda), research funding (Novartis); J.M.G.: Employment and stock\/other ownership (family member: Vertex Pharmaceuticals), consulting\/advisory role (Clinical Events Committee, ACI; AbbVie; Baim Institute; Parexel), research funding (ReCor Medical); S.E.K.: research funding (Bristol Myers Squibb, Genentech, Medtronic), consulting\/advisory role (AbbVie, Abbott, AstraZeneca, BMS, Janssen, Takeda, Medtronic); V.M.: Consulting\/advisory role (Takeda, Novartis, Amgen, Bayer), honoraria (Amgen, Novartis), research funding (Novartis, Rigel); M.C.P.: Endpoint adjudication committee (Takeda); J.S.: Employment, leadership role, stock\/other ownership (WCG Clinical); M.M.: Consulting\/advisory role, travel\/accommodations\/expenses, and honoraria (Novartis, BMS, Pfizer, Takeda), research funding (all to institution: Sun Pharma, Novartis, BMS); K.C.: Honoraria, consulting\/advisory role, travel\/accommodations\/expenses (Takeda, Abbott, CSI, Philips, Abiomed, Cordis, Boston Scientific), research funding (Abbott, ARIAD, Takeda); E.B.: Honoraria, consulting\/advisory role, travel\/accommodations\/expenses (ARIAD); MD: Consulting\/advisory role (Blueprint, Fusion Pharma, Takeda, Humana, Ascentage Pharma, Adelphi, Medscape, Novartis), research funding (Takeda, Pfizer, Novartis, Incyte, SPARC, Blueprint, Leukemia & Lymphoma Society); A.H.: Research funding (Incyte, BMS, Novartis, Pfizer); J.P.I.: Consulting\/advisory role (AbbVie, Janssen, AstraZeneca, Novartis, TG Therapeutics, Takeda), speakers bureau (AbbVie, Janssen, AstraZeneca, Takeda), research funding (MEI, Sunesis), patents\/royalties\/other intellectual property (Sellas); F.N.: Honoraria, speakers bureau, travel\/accommodations\/expenses (Novartis, Incyte Biosciences), consulting\/advisory role (Sun Pharma), research funding (Incyte Biosciences); D.W.K.: Research funding (Novartis, BMS, Pfizer, Takeda, Sun Pharma, Il-Yang Pharm. Co., Ltd.), advisory board (Novartis, BMS); D.J.D.: Consulting\/advisory role (Incyte, Pfizer, BMS, Amgen, Novartis, Celgene, Immunogen, Takeda, Blueprint Medicines), research funding (all to institution: Novartis, AbbVie, GlycoMimetics, Blueprint Medicines); H.K.: Honoraria (AbbVie, Amgen, ARIAD, BMS, Immunogen, Orsenix, Pfizer, Agios, Takeda, Actinium Pharmaceuticals), research funding (all to institution: Pfizer, Amgen, BMS, Novartis, ARIAD, Astex Pharmaceuticals, AbbVie, Agios, Cyclacel, Immunogen, Jazz Pharmaceuticals); J.X.: Employment (Takeda); T.H.: Employment (Takeda); S.S.: Employment (Takeda); D.N.: Employment (Takeda); J.C.: Consulting\/advisory role (BMS, Novartis, Pfizer, Takeda), research funding (Novartis, Pfizer, Takeda, Sun Pharma).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}